A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant

Trial Profile

A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2016

At a glance

  • Drugs T cell replacement therapy (Primary) ; Foscarnet; Ganciclovir; Valganciclovir
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CMV-IMPACT
  • Sponsors Cell Medica
  • Most Recent Events

    • 29 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2014 Planned number of patients changed from 112 to 91 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top